Press release Communiqué de presse

Share the news     Partagez les nouvelles

Press release Communiqué de presse

September 29, 2021 29 September, 2021

Sernova Engages New York-Based LifeSci Advisors as US Investor Relations Partner

Integrated Advisory and Investor Relations Program to Focus on Elevating Company’s Visibility in US Capital Markets Ahead of Projected Corporate Milestones

September 29, 2021 6:00 a.m. EDT

LONDON, ONTARIO – September 29, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a clinical-stage leader in regenerative medicine and cell therapy therapeutics developing a potential “functional cure” for type 1 diabetes (T1D) and other chronic diseases, announced today it has engaged New York-based LifeSci Advisors LLC, a leading investor relations consultancy firm serving life science companies. LifeSci is an investor relations consultancy that will provide institutional investor communications and capital markets outreach services to help Sernova achieve its capital markets objectives via a broad array of initiatives. With a global presence, LifeSci Advisors (www.lifesciadvisors.com) provides comprehensive services designed to increase its clients’ visibility within the investment community and to educate institutional investors about the Company. The LifeSci team has substantial experience in equity capital markets and the life science industry, with long-standing relationships among leading institutional investors and senior corporate professionals that it leverages on behalf of its clients.

“We are delighted to engage LifeSci during this exciting time for Sernova,” said Dr. Philip Toleikis, President and CEO of Sernova. “With multiple potential value-creating milestones on the horizon, it is important for us to clearly communicate our value proposition to investors and the industry as we work toward achieving major inflection points. We believe LifeSci has the right team and approach to help us reach the appropriate institutional audience on a global scale, which has the potential to create substantial shareholder value as we execute against our clinical and business objectives.”

The engagement is subject to TSX Venture Exchange acceptance. Under the terms of the engagement, LifeSci Advisors will be engaged for an initial term of up to 12 months, which may be renewed by the parties. In addition to reimbursement of reasonable out-of-pocket expenses, Sernova will pay LifeSci Advisors a services fee of US$210,000.

ABOUT SERNOVA Sernova is developing regenerative medicine therapeutic solutions using a medical device (Cell Pouch™) and immune protected therapeutic cells/tissues (i.e., human donor cells, corrected human cells and stem cell- derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through cellular production of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

ABOUT SERNOVA’S CELL POUCH SYSTEM

The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins and hormones as required to treat disease.

The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently conducting a Phase I/II study at the University of Chicago. Positive initial results have been presented at several international scientific conferences.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Investors: Corey Davis, Ph.D. LifeScience Advisors, LLC cdavis@lifesciadvisors.com 212-915-2577

Corporate: Investor Relations Sernova Corp. Tel: (519) 858-5126 investorrelations@sernova.com www.sernova.com

FORWARD-LOOKING INFORMATION This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and/or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.